| | The Right LIMS for COVID-19 Research LabVantage COVID-19 LIMS keeps pace with increasing COVID-19 sample volumes and research studies. Learn how one research center uses extraction and testing workflows, CDC test methods, and more to fight the coronavirus pandemic. Download our report. |
Merck CEO Frazier says COVID-19 vaccine hype a 'grave disservice' to the public Providers rush to defend after White House effort to 'discredit' Fauci 3M pairs with MIT to develop a paper-based coronavirus diagnostic test Warp Speed initiative aims for COVID-19 vaccine production within 6 weeks: Reuters Surescripts teams up with CDC, providers to accelerate COVID-19 case reporting Patients want to keep using virtual care after COVID-19 pandemic ends, survey finds AstraZeneca taps IQVIA to 'warp speed' its U.S. pandemic vaccine research Biopharma roundup: Merck KGaA picks up COVID manufacturing work; 3M, MIT team for paper-based test CVS study: Growing number of providers see value of digital health amid COVID-19 Merck KGaA's manufacturing group could see billions from COVID-19 work: analyst electroCore’s nerve stimulator authorized for asthma patients facing COVID-19 COVID has flipped the physician job search to a seller's market, recruiters say Featured Story | By Eric Sagonowsky Politicians, government officials and pharma executives alike have been predicting a COVID-19 vaccine debut by year's end, but Merck CEO Kenneth Frazier doubts that's possible. Instead, those who are promising vaccines later this year could be hurting the overall fight against the pandemic, he figures. read more |
| |
|---|
|
Top Stories By Robert King Several provider groups blasted the White House for efforts to discredit top infectious disease expert Anthony Fauci, M.D., amid the COVID-19 pandemic. read more By Conor Hale 3M is working with researchers from the Massachusetts Institute of Technology to develop a fast COVID-19 diagnostic using a simple, paper-based test that they hope will be easy to mass produce. read more By Kyle Blankenship The Trump administration has dumped billions into COVID-19 vaccine development and manufacturing as part of its Warp Speed initiative. Now, with vaccine makers moving rapidly toward approval, the administration has high hopes at least one shot candidate will start churning out doses within the next six weeks. read more By Heather Landi Surescripts has teamed up with public health officials and laboratories to accelerate case reporting on COVID-19 cases. Find out why health IT tools are playing a critical role in efforts to combat the pandemic. read more By Heather Landi Patients adopted virtual care during the COVID-19 pandemic out of necessity but now they want those services to stick around after the health crisis is over. An Accenture survey sheds light on what patients like about communicating with their doctors via telehealth and mobile apps. read more By Ben Adams Operation Warp Speed is living up to its name as, under the project, one of the COVID-19 vaccine front-runners AstraZeneca is teaming up with life science services company IQVIA to boost its work on the shot. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner AstraZeneca inked a new deal with IQVIA to leverage its virtual trials technology to speed up U.S. studies of its coronavirus vaccine candidate. FDA scientists pinpointed areas along the virus' 'spike protein' that could trigger a strong antibody response. Plus, analysts think Merck KGaA could reap billions from its pandemic-related manufacturing work. read more By Paige Minemyer Amid the coronavirus pandemic, more providers are seeing telehealth as a critical tool to connect with patients, a new survey from CVS Health shows. read more By Eric Sagonowsky COVID-19 vaccines are moving forward at record speeds, but market watchers have cautioned about the looming manufacturing challenges. Merck KGaA, with its manufacturing services outfit, could see billions of dollars in revenue as it assists certain players with their scale-up, an analyst says. read more By Conor Hale The bioelectric therapy developer electroCore received an agency green light for its vagus nerve stimulation device, aimed at reducing exacerbations in people potentially affected by the novel coronavirus and have difficulty breathing due to asthma. read more By Tina Reed Job opportunities for doctors have dried up quite a bit in wake of the COVID-19 pandemic, at least in the short term, according to an annual report from physician search firm Merritt Hawkins. read more |
